The major concern about a powerful new gene-editing technique that most people don't want to talk about
By Tanya Lewis,
Business Insider
| 12. 02. 2015
Scientists, bioethicists, and members of the public have descended on Washington, DC this week for an international meeting to discuss the ethics of a promising lab technique that lets scientists edit our genes.
The technique, known as CRISPR/Cas9, lets scientists cut-and-paste DNA inside cells to correct genetic defects or, potentially, add new capabilities. It offers enormous promise to improve our understanding of biology and to treat or even eliminate genetic diseases.
But there's a dark side to manipulating our genetics that few want to discuss: Eugenics, the racist practice of trying to "improve" the human race by controlling genetics and reproduction.
A disturbingly widespread practice
While eugenics is most commonly associated with Nazi Germany, it was alive and well in the US and in other countries well before World War II, Daniel Kevles, a historian of science at New York University, said during a talk at the gene editing summit on Tuesday.
"Eugenics was not unique to the Nazis. It could — and did — happen everywhere," Kevles said.
He and others worry that gene editing tools like CRISPR...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...